Herpes simplex virus combined subunit vaccines and methods of use thereof
AssigneeThe Trustees of the University of Pennsylvania
InventorsHarvey Friedman, Sita Awasthi, John Lubinski
Life of this patent
Estimating the term…
Abstract
This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention.
Claims40
An immunogenic composition comprising two or three recombinant Herpes Simplex Virus type 2 (HSV-2) glycoproteins and an adjuvant, said two or three glycoproteins consisting of:
- (a) a recombinant HSV-2 glycoprotein E (gE) or immunogenic fragment thereof, wherein said gE fragment comprises amino acids 24-224 or 24-409 of gE as set forth in SEQ ID NO:
- 6;
- and
- (b) a recombinant HSV-2 glycoprotein D (gD) or immunogenic fragment thereof, a recombinant HSV-2 glycoprotein C (gC) or fragment thereof, or a combination thereof,
- wherein said gC fragment comprises a C3b-binding domain of gC,
- wherein said immunogenic composition does not comprise HSV-2 glycoprotein B (gB);
- and
- wherein said immunogenic composition has a synergistically greater anti-HSV immune evasion function-blocking as compared with anti-HSV immune evasion function-blocking of one of the components of said immunogenic composition.
An immunogenic composition comprising two or three recombinant Herpes Simplex Virus type 2 (HSV-2) glycoproteins and an adjuvant, said two or three glycoproteins consisting of:
- (a) a recombinant HSV-2 glycoprotein E (gE) or immunogenic fragment thereof, wherein said gE fragment comprises amino acids 24-224 or 24-409 of gE as set forth in SEQ ID NO:
- 6;
- and
- (b) a recombinant HSV-2 glycoprotein C (gC) or fragment thereof;
- and
- (c) optionally, a recombinant HSV-2 glycoprotein D (gD) or immunogenic fragment thereof,
- wherein said gC fragment consists of amino acids 27-426 of SEQ ID NO:
- 4 or a homolog thereof from another HSV-2 strain;
- and wherein said immunogenic composition does not comprise HSV-2 glycoprotein B (gB).
Dependencies are inferred from the claim text.